烟酰胺单核苷酸增强靶向 MSLN 的 CAR-NK 细胞治疗在卵巢癌中的抗肿瘤疗效

Nicotinamide mononucleotide potentiates the anti-tumor efficacy of CAR-NK cell therapy targeting MSLN in ovarian cancer.

化学预处理通过改善肿瘤迁移与细胞毒性杀伤动力学增强靶向间皮素的嵌合抗原受体工程化 NK-92 抗肿瘤活性

Chemical priming potentiates mesothelin-targeting chimeric antigen receptor-engineered NK-92 antitumor activity by improving tumor trafficking and cyt

这些发现表明，化学预处理可增强 CAR-NK 细胞功能，并提供了一种有前景的非基因策略来提升 CAR-NK 细胞对实体瘤模型的活性。

嵌合抗原受体 NK 细胞治疗卵巢癌的疗效：临床前研究的荟萃分析

Efficacy of chimeric antigen receptor natural killer cells in treatment of ovarian cancer. A meta-analysis of pre-clinical studies.

CAR-T 与 CAR-NK 细胞疗法治疗卵巢癌的当前进展

Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.

间皮素作为癌症治疗中的信号通路和表观遗传靶点

Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy.

Neoleukin-2/15 装甲 CAR-NK 细胞通过 c-Myc/NRF1 激活在实体瘤中维持优越的治疗效果

Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation.

重定位抗间皮素 CAR-NK 免疫治疗用于结直肠癌

Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.

我们的结果提供了临床前证据，表明表达高水平间皮素的结直肠癌亚群可被基于 MSLN-CAR 的免疫治疗有效靶向。

人胚胎干细胞来源的间皮素 CAR 工程化 NK 细胞抑制动物体内人卵巢癌进展

Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals.